Search
Search Results
-
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
BackgroundBAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several...
-
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
BackgroundGlioblastoma (GBM), the most lethal primary brain tumor, has limited treatment options upon recurrence after chemoradiation and...
-
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
Background and ObjectiveHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide, especially in China. According...
-
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors
BackgroundThe combination of paclitaxel to platinum remains the backbone of therapy in patients with advanced Mullerian tumors. In patients with...
-
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
IntroductionGlioblastoma (GBM) is the most common central nervous system malignancy in adults. Despite decades of developments in surgical...
-
Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
ObjectiveThis study aimed to determine whether the combined use of bevacizumab could improve overall survival (OS) in patients with brain metastasis...
-
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
BackgroundPF-06439535 (bevacizumab-bvzr; Zirabev ® ) is a biosimilar of bevacizumab reference product (RP; Avastin ® ). This study describes the...
-
Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China
BackgroundBevacizumab shows superior efficacy in cerebral radiation necrosis (CRN) therapy, but its economic burden remains heavy due to the high...
-
Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity
PurposeTo compare the results of intravitreal bevacizumab (IVB) monotherapy and combined intravitreal bevacizumab and laser photocoagulation (LPC)...
-
Outcomes of systemic bevacizumab in radiation-induced optic neuropathy, case series
PurposeOptic neuropathy is a rare, delayed complication after radiation with no universally accepted treatment modality. We report the outcomes of 6...
-
Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
BackgroundTo date, evidence has been lacking regarding bevacizumab pharmacokinetics in the cerebrospinal fluid (CSF).
ObjectiveThis study assessed...
-
The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab
PurposeBevacizumab has evolved as an integral treatment option for patients with high-grade gliomas. Little is known about clinical risk factors that...
-
Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab
Background and objectivesProteinuria is a common complication after the application of bevacizumab therapy in patients with metastatic colorectal...
-
Intralesional cidofovir vs. bevacizumab for recurrent respiratory papillomatosis: a systematic review and indirect meta-analysis
BackgroundSpecific HPV types cause recurrent respiratory papillomatosis (R.R.P.). When administered intralesionally, cidofovir, an antiviral agent,...
-
Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response
BackgroundAutopsy-based radio-pathomic maps of glioma pathology have shown substantial promise inidentifying areas of non-enhancing tumor presence,...
-
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
BackgroundIn the PAOLA-1 trial, olaparib plus bevacizumab demonstrated significant clinical benefit following partial or complete response to...
-
Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma
BackgroundImmune checkpoint inhibitor (ICI)-based treatments have become the mainstay of first-line treatment for unresectable hepatocellular...
-
Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion
BackgroundSeveral studies have indicated that intrapleural infusion of bevacizumab is an effective treatment for non-small cell lung cancer (NSCLC)...
-
Real-world evidence in the use of Bevacizumab in age-related macular degeneration (ArMD): a sco** review
PurposePharmacological treatments for age-related macular degeneration (ArMD) include anti-vascular endothelial growth factor therapies. Bevacizumab...
-
Comparative analysis of bevacizumab and LITT for treating radiation necrosis in previously radiated CNS neoplasms: a systematic review and meta-analysis
PurposeRadiation necrosis (RN) is a local inflammatory reaction that arises in response to radiation injury and may cause significant morbidity. This...
